Steven Anliker, NP
Family · Chattanooga, TNNPI 1558607580
Payments from drug & device makers
Across 343 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$832
- Pfizer$485
- Merck$433
- Boehringer Ingelheim$418
- Actelion Pharmaceuticals US, Inc.$415
- Johnson & Johnson$381
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,76298%
- Education$1402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 65 | $832 |
| Pfizer | 31 | $485 |
| Merck | 22 | $433 |
| Boehringer Ingelheim | 23 | $418 |
| Actelion Pharmaceuticals US, Inc. | 23 | $415 |
| Johnson & Johnson | 25 | $381 |
| AstraZeneca | 13 | $327 |
| E.r. Squibb & Sons, L.L.C. | 28 | $293 |
| United Therapeutics Corporation | 13 | $287 |
| Abbott | 7 | $247 |
| Novo Nordisk | 12 | $211 |
| Amgen | 10 | $188 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $151 |
| Baxter Healthcare | 6 | $141 |
| Lexicon Pharmaceuticals, Inc. | 7 | $131 |
| Boston Scientific | 7 | $118 |
| Scpharmaceuticals Inc. | 5 | $106 |
| Heartflow, Inc. | 1 | $88 |
| Irhythm Technologies, Inc. | 4 | $77 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $68 |
| Alnylam Pharmaceuticals Inc. | 3 | $62 |
| Amarin Pharma, Inc. | 3 | $61 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Vital Connect, Inc | 1 | $33 |
| Davol Inc. | 1 | $31 |
| Cvrx, Inc. | 1 | $26 |
| Mannkind Corporation | 1 | $26 |
| Preventice Services, LLC | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Biosense Webster, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$133
- WAINUA$103
- FARXIGA$103
How this compares
$5,902 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 241 | $235,651 |
| OzempicSemaglutide | 209 | $220,847 |
| JardianceEmpagliflozin | 217 | $198,052 |
| EliquisApixaban | 164 | $129,584 |
| FarxigaDapagliflozin Propanediol | 139 | $118,457 |
| Ambrisentan | 13 | $64,454 |
| MounjaroTirzepatide | 53 | $51,743 |
| XareltoRivaroxaban | 36 | $47,736 |
| Repatha SureclickEvolocumab | 40 | $23,325 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $9,461 |
| CorlanorIvabradine Hcl | 13 | $8,227 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 77 | $3,685 |
| Diltiazem 12hr ErDiltiazem Hcl | 14 | $3,110 |
| Spironolactone | 329 | $2,932 |
| Ranolazine ErRanolazine | 29 | $2,877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $832 | $235,651241 claims |
| Novo NordiskOzempic | $211 | $220,847209 claims |
| Boehringer IngelheimJardiance | $418 | $198,052217 claims |
| PfizerEliquis | $485 | $129,584164 claims |
| AstraZenecaFarxiga | $327 | $118,457139 claims |
| Johnson & JohnsonXarelto | $381 | $47,73636 claims |
| AmgenCorlanor | $188 | $8,22713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Chattanooga
- Jennifer SparksChattanooga$120K
- Marcie BeasleyChattanooga$91K
- Amy RainsChattanooga$55K
- Bronte NaplesChattanooga$26K
- Ernest BrandtChattanooga$21K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.